Lemoine, 1997 - Google Patents
Molecular advances in pancreatic cancerLemoine, 1997
- Document ID
- 18297224027522678254
- Author
- Lemoine N
- Publication year
- Publication venue
- Digestion
External Links
Snippet
Our understanding of the molecular genetics of pancreatic cancer has advanced spectacularly over the last 5 years so that this tumour type is now one of the best characterised of all malignancies. A small proportion of cases results from inherited …
- 208000008443 Pancreatic Carcinoma 0 title abstract description 24
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | A comprehensive review of pancreatic cancer and its therapeutic challenges | |
| Silva et al. | Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients | |
| EP3781196B1 (en) | Sequence-specific in vivo cell targeting | |
| Albany et al. | Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine | |
| Virmani et al. | Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer | |
| Lemoine | Molecular advances in pancreatic cancer | |
| Gabrilovich | INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer | |
| KR20190039115A (en) | CRISPR / CAS9-based compositions and methods for treating cancer | |
| Philippi et al. | Telomerase as an emerging target to fight cancer—Opportunities and challenges for nanomedicine | |
| Fang et al. | Tumor suppressing gene therapy | |
| Li et al. | Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy | |
| Boulware et al. | Triplex‐forming oligonucleotides targeting c‐Myc potentiate the anti‐tumor activity of gemcitabine in a mouse model of human cancer | |
| Wang et al. | Chemosensitization and radiosensitization of human cancer by antisense anti‐MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms | |
| CN101273130B (en) | Nucleic acid substances for down-regulating H19 and methods of use thereof | |
| Thege et al. | A programmable in vivo CRISPR activation model elucidates the oncogenic and immunosuppressive functions of MYC in lung adenocarcinoma | |
| Lee et al. | Therapeutic applications of group I intron‐based trans‐splicing ribozymes | |
| Menezes et al. | Prospects of gene therapy to treat melanoma | |
| Yang et al. | Gene targets of antisense therapies in breast cancer | |
| Kokkinakis et al. | Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O 6-Methylguanine-DNA methyltransferase with O 6-benzylguanine or O 6-benzyl-2′-deoxyguanosine | |
| WO2019181305A1 (en) | CANCER PROLIFERATION INHIBITOR COMPRISING snoRNA EXPRESSION INHIBITOR AS ACTIVE INGREDIENT | |
| Chu et al. | Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells | |
| KR101168726B1 (en) | Pharmaceutical composition for treating cancer | |
| Xu et al. | Current status of gene therapy in gastroenterology | |
| DUGGAN et al. | Molecular targets for the therapeutic manipulation of apoptosis in bladder cancer | |
| Tong et al. | Molecular aspects of ovarian cancer: Is gene therapy the solution? |